ClinicalTrials.gg
CompletedNCT05749055ENCALMUpdated Sep 21, 2026

ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder

A Phase 2 interventional study of ENX-102 and Placebo in Generalized Anxiety Disorder, sponsored by Engrail Therapeutics INC. Completed at 32 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Engrail Therapeutics INC · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Sep 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 265 studies in Generalized Anxiety Disorder with a site in United States — 38 open to participants now, 53 under way, 9 of them phase 3. Generalized Anxiety Disorder · United States.

Enrollment
64th of 234
252 · median 90
Started
2023
with 9 others
Phase 2
21 of 265
5 open now
Registered
215th of 265
by date

Among the 265 studies in Generalized Anxiety Disorder with a site in United States, this one is the 64th largest by enrollment of the 234 interventional ones that give a count, is one of 10 that started in 2023, is one of 21 in phase 2, and was the 215th registered.

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

Browse Generalized Anxiety Disorder studies →

Open to participants now

38 of the 265 studies in Generalized Anxiety Disorder with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 52 (60%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Generalized Anxiety Disorder with a site in United States, or all of them as a file.
02

Study summary

The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)

03

Conditions studied

  • Generalized Anxiety Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female at birth, inclusive of any gender identity, aged 18 to 65 years, inclusive, at Screening
  • Diagnosed with GAD according to the , Fifth Edition (DSM-5), confirmed by a Mini-International Neuropsychiatric Interview (MINI) version 7.0.2
  • Experiencing generalized anxiety in need of treatment as measured by Hamilton Anxiety Rating Scale (HAM-A) Screening and Day 1 scores ≥22 and at least moderately severe score symptoms of anxious mood and tension as measured by HAM-A items 1 and 2, respectively, with score each ≥2 at Screening and Day 1

Key Exclusion Criteria:

  • Clinically predominant psychiatric diagnosis other than GAD as confirmed by the MINI
  • Any past/lifetime/current diagnosis of a neurocognitive disorder, or psychotic disorder, or any current diagnosis of posttraumatic stress disorder, obsessive compulsive disorder or bipolar disorder confirmed by independent adjudication
  • Reports moderately severe to severe symptoms of depression
  • Ingested psychotropic medication within 5 half-lives or 21 days (whichever is longer) prior to Day 1, including THC and CBD, and unwillingness to refrain from their use for the entire duration of the trial
  • Recent suicidal ideation or behavior
  • Current or recent moderate to severe substance use disorder as assessed by the MINI
  • Clinically significant abnormal findings in safety assessments
  • Has significant progressive disorders or unstable medical conditions
  • Unable to comply with the requirements of the study or, in the opinion of the Investigator or Sponsor, is unsuitable for the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
252 participants (actual)

Study arms

  • Experimental
    ENX-102

    Four weeks of 2 mg of ENX-102 in capsule form followed by 3 weeks of tapered dose plus 2 weeks of placebo in capsule form (before and/or after the ENX-102 treatment period), taken orally once daily in the evening for a 9-week total treatment period.

    Drug: ENX-102

  • Placebo comparator
    Placebo

    Nine weeks of placebo in capsule form taken orally once daily in the evening for a 9-week total treatment period.

    Drug: Placebo

Interventions

  • Selective GABA-A alpha2,3,5 positive allosteric modulator

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. To evaluate the efficacy of ENX-102 versus placebo in patients with generalized anxiety disorder (GAD)

    Mean change from baseline on the Hamilton Anxiety Rating Scale (HAM-A) total score \[14 symptoms with each symptom scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56 and higher scores representing worse outcomes\]

    Time frame: 4 weeks

07

Study locations

32 sites
  • IMA Clinical Research Phoenix
    Phoenix, Arizona 85012, United States
  • Collaborative Neuroscience Research, LLC (CNS)
    Garden Grove, California 92845, United States
  • Sun Valley Research Center
    Imperial, California 92251, United States
  • Alliance Research
    Long Beach, California 90712, United States
  • NRC Research Institute
    Los Angeles, California 90015, United States
  • Excell Research, Inc.
    Oceanside, California 92056, United States
  • Anderson Clinical Research
    Redlands, California 92374, United States
  • California Neuroscience Research, LLC
    Sherman Oaks, California 91403, United States
  • Pacific Clinical Research Management Group
    Upland, California 91786, United States
  • Sunwise Clinical Research
    Walnut Creek, California 94596, United States
  • Mountain View Clinical Research
    Denver, Colorado 80209, United States
  • Vertex Clinical Research
    Clermont, Florida 34711, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32256, United States
  • Accel Research Sites Network - Lakeland CRU
    Lakeland, Florida 33803, United States
  • Accel Research Sites Network - Maitland CRU
    Maitland, Florida 32751, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
  • CenExel iResearch, LLC
    Savannah, Georgia 31405, United States
  • Collective Medical Research
    Overland Park, Kansas 66210, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • Precise Research Centres
    Flowood, Mississippi 39232, United States
  • IMA Clinical Research
    Las Vegas, Nevada 89102, United States
  • SPRI Clinical Trials, LLC
    Brooklyn, New York 11235, United States
  • Neurobehavioral Research
    Cedarhurst, New York 11516, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10314, United States
  • Clinical Neuroscience Solutions, Inc.
    Memphis, Tennessee 38119, United States
  • Austin Clinical Trials Partners
    Austin, Texas 78737, United States
  • FutureSearch Trials of Dallas
    Dallas, Texas 75231, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Aim Trials
    Plano, Texas 75093, United States
  • Grayline Research Center
    Wichita Falls, Texas 76309, United States
  • Alpine Research Organization
    Clinton, Utah 84015, United States
  • Core Clinical Research
    Everett, Washington 98201, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Sep 2025, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2023
First posted
Mar 1, 2023
StartActual
Jul 3, 2023
Primary completionActual
Sep 18, 2025
CompletionActual
Sep 18, 2025
Results delay requested
Sep 17, 2026
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05749055
Lead sponsor
Engrail Therapeutics INC
Responsible party
Sponsor
First posted
Mar 1, 2023
Start date
Jul 3, 2023
Primary completion
Sep 18, 2025
Completion
Sep 18, 2025
Last update
Sep 21, 2026

Study contacts

Estibaliz Arce, PhD
study director · Engrail Therapeutics INC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ENX-102

Start the discussion